Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis

European Urology

Volumn 70, Issue 1, 2016, Pages 21-30

  Wallis, Christopher J D ^a,b,c   Saskin, Refik ^a,c   Choo, Richard ^d   Herschorn, Sender ^a,b   Kodama, Ronald T ^a,b   Satkunasivam, Raj ^a,b   Shah, Prakesh S ^c,e,f   Danjoux, Cyril ^b   Nam, Robert K ^a,b,c  

^a Canada   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MAYO CLINIC   (United States)

^e MOUNT SINAI HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Brachytherapy; Mortality; Prostatectomy; Prostatic neoplasms; Radiotherapy; Retropubic; Survival

Indexed keywords

BRACHYTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL DECISION MAKING; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; NEWCASTLE OTTAWA SCALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RATING SCALE; REVIEW; SYSTEMATIC REVIEW; COMPARATIVE STUDY; INTENSITY MODULATED RADIATION THERAPY; MALE; MORTALITY; PATHOLOGY; PROSTATE TUMOR; SURVIVAL RATE;

BRACHYTHERAPY; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL RATE;

EID: 84950242673     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.11.010     Document Type: Review

References (28)

1. [1] Heidenreich, A., Bastian, P.J., Bellmunt, J., et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65 (2014), 124–137.
2. [2] Mohler, J., Bahnson, R.R., Boston, B., et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 8 (2010), 162–200.
3. [3] Ontario CC. Prostate cancer treatment pathway: Version 2012.11. https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileID=298448.
4. [4] Lei, J.H., Liu, L.R., Wei, Q., et al. Systematic review and meta-analysis of the survival outcomes of first-line treatment options in high-risk prostate cancer. Sci Rep, 5, 2015, 7713.
5. [5] Petrelli, F., Vavassori, I., Coinu, A., Borgonovo, K., Sarti, E., Barni, S., Radical prostatectomy or radiotherapy in high-risk prostate cancer: a systematic review and metaanalysis. Clin Genitourin Cancer 12 (2014), 215–224.
6. [6] Sooriakumaran, P., Nyberg, T., Akre, O., et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ, 348, 2014, g1502.
7. [7] Merino, T., San Francisco, I.F., Rojas, P.A., Bettoli, P., Zuniga, A., Besa, P., Intensity-modulated radiotherapy versus radical prostatectomy in patients with localized prostate cancer: long-term follow-up. BMC Cancer, 13, 2013, 530.
8. [8] Lee, J.Y., Cho, K.S., Kwon, J.K., et al. A competing risk analysis of cancer-specific mortality of initial treatment with radical prostatectomy versus radiation therapy in clinically localized high-risk prostate cancer. Ann Surg Oncol 21 (2014), 4026–4033.
9. [9] Kibel, A.S., Ciezki, J.P., Klein, E.A., et al. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol 187 (2012), 1259–1265.
10. [10] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151 (2009), 264–269.
11. [11] Stroup, D.F., Berlin, J.A., Morton, S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting, Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283 (2000), 2008–2012.
12. [12] Deeks, J.J., Dinnes, J., D'Amico, R., et al. Evaluating non-randomized intervention studies. Health Technol Assess, 7, 2003 iii–x, 1–173.
13. [13] Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses, 2011. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
14. [14] Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
15. [15] Zelefsky, M.J., Eastham, J.A., Cronin, A.M., et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 28 (2010), 1508–1513.
16. [16] Tierney, J.F., Stewart, L.A., Ghersi, D., Burdett, S., Sydes, M.R., Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8, 2007, 16.
17. [17] Xiong, T., Turner, R.M., Wei, Y., Neal, D.E., Lyratzopoulos, G., Higgins, J.P., Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis. BMJ Open, 4, 2014, e004285.
18. [18] Stevens, D.J., Sharma, N.L., Tewari, A.K., Kirby, R., Sooriakumaran, P., Organ-confined prostate cancer: are we moving towards more or less radical surgical intervention?. Curr Urol Rep, 16, 2015, 27.
19. [19] Paulson, D.F., Lin, G.H., Hinshaw, W., Stephani, S., Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 128 (1982), 502–504.
20. [20] Akakura, K., Suzuki, H., Ichikawa, T., et al. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol 36 (2006), 789–793.
21. [21] Collaborators, P.R., Early closure of a randomized controlled trial of three treatment approaches to early localised prostate cancer: the MRC PR06 trial. BJU Int 94 (2004), 1400–1401.
22. [22] Wilt, T.J., Can randomized treatment trials in early stage prostate cancer be completed?. Clin Oncol (R Coll Radiol) 10 (1998), 141–143.
23. [23] Kalbasi, A., Li, J., Berman, A., et al. Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer. JAMA Oncol 1 (2015), 897–906.
24. [24] Westover, K., Chen, M.H., Moul, J., et al. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer. BJU Int 110 (2012), 1116–1121.
25. [25] Boorjian, S.A., Karnes, R.J., Viterbo, R., et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 117 (2011), 2883–2891.
26. [26] Giordano, S.H., Kuo, Y.F., Duan, Z., Hortobagyi, G.N., Freeman, J., Goodwin, J.S., Limits of observational data in determining outcomes from cancer therapy. Cancer 112 (2008), 2456–2466.
27. [27] Nguyen, P.L., Gu, X., Lipsitz, S.R., et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 29 (2011), 1517–1524.
28. [28] Lane, J.A., Donovan, J.L., Davis, M., et al. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomized phase 3 trial. Lancet Oncol 15 (2014), 1109–1118.